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Letters to the Editor 
Sir, 
Patient to patient hepatitis B transmission during heart biopsy 
procedures. A report of the European Working Party on Viral Hepatitis 
in Heart Transplant Recipients 
Hepatitis B virus (HBV) is an hepatotropic DNA virus. Important routes 
of horizontal transmission of the virus are through blood or blood products, 
by sexual contact and by organ transplantation. After an acute infection, 
S-10% of immunocompetent adult patients and 90-100% of patients on 
immunosuppressive therapy or who acquire HBV via vertical transmission 
will develop chronic hepatitis B. 
In general, heart transplant recipients are screened for the absence of 
HBsAg and anti-HBc before being accepted for transplantation. Organ 
donors, as well as blood donors, are screened for the absence of HBsAg 
before being accepted.’ However, we think that it is important to draw the 
attention of transplant cardiologists, thoracic surgeons, hepatologists and 
those involved in hospital infection control to the risk of nosocomial 
transmission of hepatitis B virus during endomyocardial biopsy procedures. 
Complete epidemiological data are now published from the Hannover group 
and have been submitted for publication from the Rotterdam and Paris 
groups.2,3,4,5 In Hannover hepatitis B was diagnosed in 67 patients in a five- 
year period (crude attack rate 27.5%). In Paris, 86 cases of HBV infection 
were diagnosed in an 11 -year period (crude attack rate 11.5%). In Rotterdam, 
21 cases were diagnosed in a 12-year period (crude attack rate 8.2%). How 
can this be explained? 
Most infected heart transplant recipients will not develop severe liver 
enzyme abnormalities or hyperbilirubinaemia or have signs or symptoms 
compatible with hepatitis B infection. Therefore, recognition of an infected 
patient will require a high index of suspicion. For the reason mentioned 
above, infection will become chronic with high levels of viraemia. The 
amount of HBV DNA present can be up to 10” genome equivalents per 
millilitre blood. In addition, one of the features of heart transplant recipients 
is that during follow-up they will have numerous invasive procedures, 
especially repeated right-sided endomyocardial biopsy. This makes the 
patient vulnerable to patient-patient or patient-doctor transmission from 
a highly contagious index patient. 
In three heart transplant units, an epidemic outbreak of hepatitis B in 
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heart transplant recipients has now been documented. In all centres, case- 
controlled analysis showed that after introduction of an infected patient 
(index patient) patient-patient transmission occurred during routine right- 
sided endomyocardial biopsy procedures in the post-transplantation phase. 
Several common factors could be identified but the most important ob- 
servation was that in some centres not all of the infection control guidelines 
for this biopsy, as proposed for heart catheterization, had been applied. We 
strongly recommend that right-sided endomyocardial biopsy be considered 
as an invasive procedure that merits infection control practices at least as 
strict as those proposed for heart catheterization.6 If transplant units 
consider vaccination against hepatitis B candidate recipients as soon as they 
are put on the waiting list; in the post-transplant period less than 5% of 
patients will respond to primary vaccination (anti-HBs>lO IU/L).7 
Because this problem may be common to several heart-transplant units, 
our group has started a ‘European Registry on Viral Hepatitis in Heart 
Transplant Recipients’ to study the determinants of the outcome of the 
disease and to coordinate future interventions. We would welcome any 
centre that is willing to contribute their experience and collaborate with 
us. 
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Sir, 
Creative infection control-raising awareness of infection control 
policies 
Following the recent article in the Journal describing various activities 
designed to increase interest in infection control,’ the control of infection 
team at this hospital implemented one of the programmes mentioned, 
namely, a ‘Hospital Handwash Day’. 
Staff were targeted as they arrived at the hospital canteen for lunch, and 
asked to place a hand on a blood agar plate. Identification was by ticket to 
preserve anonymity. They were asked also to complete a brief questionnaire 
detailing the timing of their most recent handwash. Relevant posters 
adorned the hospital canteen entrance. Plates were incubated in air overnight 
and colony forming units (cfus) identified and quantified by standard 
laboratory procedures. The results were posted on a notice-board directly 
outside the canteen one week later, together with explanatory notes regarding 
the isolates found and prizes awarded for the ‘Cleanest Hand’, the ‘Dirtiest 
Hand’ and the hand producing the ‘Most Unusual Organism’. Hands from 
139 members of staff were captured on plate, and 119 questionnaires 
completed. Most hands carried coagulase-negative staphylococci and 
diptheroids, but five (4%) produced coliforms, five (4%) faecal streptococci, 
12 (9%) Staphylococcus aureu~ (none methicillin-resistant) and one (~1%) 
